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NLRP3 nucleates the inflammasome, a protein com-
plex responsible for cleavage of prointerleukin-1b
(IL-1b) to its active form. Mutations in the NLRP3
gene cause the autoinflammatory disease spectrum
cryopyrin-associated periodic syndromes (CAPS).
The central role of IL-1b in CAPS is supported by
the response to IL-1-targeted therapy. We developed
two Nlrp3 mutant knockin mouse strains to model
CAPS to examine the role of other inflammatory
mediators and adaptive immune responses in an
innate immune-driven disease. These mice had
systemic inflammation and poor growth, similar to
some human CAPS patients, and demonstrated early
mortality, primarily mediated by myeloid cells.
Mating these mutant mice to various gene mutant
backgrounds showed that the mouse disease
phenotype required an intact inflammasome, was
only partially dependent on IL-1b, and was indepen-
dent of T cells. These data suggest that CAPS are
true inflammasome-mediated diseases and provide
insight for more common inflammatory disorders.
INTRODUCTION
NLRP3 (also known as Cryopyrin, NALP3, CIAS1) is a prototype
of the nucleotide-binding domain and leucine-rich repeat-con-
taining (NLR) family, a group of intracellular innate immune
proteins thought to act as sensors of pathogen- and damage-
associated molecular patterns (PAMPs and DAMPs) (Martinon
and Tschopp, 2005). NLRP3 is capable of forming an inflamma-
some, a macromolecular complex that directs activation of the
IL-1-converting enzyme caspase-1, resulting in cleavage and
secretion of the proinflammatory mediator IL-1b, as well as
IL-18 and IL-33 (Martinon, 2008; Meylan et al., 2006; Schmitzet al., 2005). NLRP3’s importance as a regulator of inflammation
was made clear when dominantly inherited mutations in the
NLRP3 gene were proven responsible for a spectrum of inflam-
matory diseases, including familial cold autoinflammatory
syndrome (FCAS), Muckle-Wells syndrome (MWS), and neonatal
onset multisystem inflammatory disease (NOMID), now collec-
tively referred to as the cryopyrin-associated periodic syn-
dromes (CAPS) (Aksentijevich et al., 2002; Feldmann et al.,
2002; Hoffman et al., 2001).
CAPS represent a continuum in disease severity, with FCAS at
the mild end, manifesting cold-induced inflammatory episodes,
MWS in the middle with attacks potentially leading to long-
term sequelae such as amyloidosis, and NOMID, most severe,
with continuous inflammation causing neurological impairment
and deforming arthropathy (Aksentijevich et al., 2007). Patients
lack high-titer autoantibodies and self-reactive T cells, so
CAPS fall under the rubric of autoinflammation, a class of condi-
tions considered separate from autoimmunity in that pathology
is thought to arise from dysregulation of the innate immune
system, with little or no contribution from adaptive immunity.
The inflammasome has been implicated indirectly in the path-
ogenesis of other Mendelian autoinflammatory disorders, such
as familial Mediterranean fever (Chae et al., 2003; Stehlik et al.,
2003; Yu et al., 2007) and the syndrome of pyogenic arthritis,
pyoderma gangrenosum, and acne (Wise et al., 2002). The in-
flammasome also appears to play a role in complex diseases
such as gout and asbestosis, in which monosodium urate crys-
tals and asbestos fibers act as DAMPS to trigger IL-1-mediated
inflammation (Dostert et al., 2008; Martinon et al., 2006).
Mutations in NLRP3 are thought to result in inappropriate acti-
vation of the inflammasome, leading to excessive IL-1b release
and CAPS disease manifestations. Treatment with the IL-1b
inhibitors Rilonacept or Anakinra prevents episodes in MWS
and FCAS and resolves most inflammatory signs and symptoms
in NOMID (Hoffman et al., 2008). However, there is an emerging
body of data suggesting thatmutations in NLRP3may have other
effects besides increased IL-1b. A recent publication demon-
strated that CAPS mutations increase necrotic-like cell deathImmunity 30, 875–887, June 19, 2009 ª2009 Elsevier Inc. 875
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(Willingham et al., 2007). Because necrosis releases proinflam-
matory mediators normally sequestered in cells, this pathway
may also lead to inflammation and provide a possible explana-
tion for why some CAPS patients have incomplete clinical
responses to Anakinra and Rilonacept (Goldbach-Mansky
et al., 2006; Hoffman et al., 2008).
Efforts to dissect the role of the inflammasome in CAPS have
been hampered by the limitations of working with patient tissue
samples, the heterogeneity intrinsic to humans, and the lack of
specific inflammasome inhibitors. Although a mouse model of
uncontrolled IL-1b signaling is available (the IL-1 receptor antag-
onist-deficient mouse) (Horai et al., 2000), this model does not
address IL-1b-independent functions of the inflammasome.
We therefore engineered mutations associated with two specific
phenotypes (FCAS and MWS) into mouse Nlrp3 to examine the
roles of IL-1b and other cytokines, as well as to characterize
inflammasome functions beyond the innate immune system.
The results presented here show that CAPS mutations lead to
severe inflammatory disease in mice dependent on the inflam-
masome and the myeloid lineage. The major physiological
consequence of CAPS-associated inflammasome activation is
IL-1bmediated, but other effectors are clearly involved. Although
a robust T cell response was observed, it was not necessary for
disease, demonstrating a marked predominance of innate
immunity in the pathogenesis of CAPS inflammasomopathies
that may be extended to autoinflammation in general.
RESULTS
Development of Nlrp3A350VneoR/+ and Nlrp3L351PneoR/+
Mice
To gain a better understanding of CAPS disease processes, we
generated two knockin mouse strains. The alanine 352 to valine
(A352V) and leucine 353 to proline (L353P) mutations were
chosen because they are strongly associated with classical
MWS and FCAS patients, respectively, and less so in patients
with overlap syndromes (Hoffman et al., 2001, 2003). Second,
these mutations affect adjacent amino acids and are predicted
to affect a surface involved in interdomain or interprotein interac-
tions in the assembled inflammasome (Figure S1A). The A352
and L353 residues (A350 and L351 in mouse NLRP3) are
conserved in mouse and human NLRP3, as is the immediate
protein environment of these residues in models of the NLRP3
structure (Aksentijevich et al., 2007).
To mutate these residues, we engineered a construct intro-
ducing a floxed neomycin resistance cassette into intron 2,
directly upstream of alanine 350 and leucine 351. Embryonic
stem cell colonies positive for the A350V or L351P mutations
were used to create chimeric mice, which then yielded offspring
heterozygous for A350V or L351P, lines Nlrp3A350VneoR/+ and
Nlrp3L351PneoR/+ (Figure S1B). Sequence analysis of cDNA from
Nlrp3A350VneoR/+ and Nlrp3L351PneoR/+ mice demonstrated lack
of expression from themutated alleles, consistent with transcrip-
tional silencing resulting from the reverse orientation of the
neomycin resistance cassette (neoR) relative to the Nlrp3 gene.
We therefore bred these mice to various lines expressing Cre re-
combinase under control of different promoters: zona pelucida 3
(CreZ: recombinase expression prior to completion of the first876 Immunity 30, 875–887, June 19, 2009 ª2009 Elsevier Inc.meiotic division, all cells expressing cryopyrin express A350V/
L351P) (Lewandoski et al., 1997), lysozyme (CreL: A350V/
L351P expression in myeloid lineage cells only) (Clausen et al.,
1999), and tamoxifen-inducible, with Cre recombinase fused to
the estrogen-responsive protein (CreT: A350V/L351P expres-
sion induced upon exposure to 4-hydroxytamoxifen) (Hayashi
andMcMahon, 2002). The mouse lines generated are as follows:
Nlrp3A350V/+CreZ; Nlrp3A350V/+CreL; Nlrp3A350V/+CreT and
Nlrp3L351P/+CreZ; Nlrp3L351P/+CreL; and Nlrp3L351P/+CreT. PCR
and cDNA sequencing showed that the mutant alleles were
now being expressed (Figure S1C).
Embryonic or Myeloid-Specific Expression of A350V
or L351P Results in Neonatal Lethality
Nlrp3A350V/+CreZ pups demonstrated an inflammatory pheno-
type approximately 1–2 days after birth, developing skin
abscesses that gave way to scaling erythema by day 4. In addi-
tion, these mice exhibited profound growth delay with lack of
pigmentation and hair growth observable by day 4. Although
Nlrp3 wild-type (CreZ or CreL) mice grew steadily from birth,
mutant pups gained weight slowly, and then lost weight before
dying between days 2 and 14 (Figure 1A). Nlrp3A350V/+CreL
pups demonstrated a similar phenotype, but had different
mortality kinetics such that 70% of these mice survived until
day 7–9 before dying at an increased rate (p < 0.0001; Figure 1A).
Although different from the urticaria-like lesions seen in MWS
patients, the cutaneous erythema, abscesses, and scaling
observed in pups expressing A350V nevertheless suggested
underlying inflammation. Hematoxylin and eosin staining of
various tissues showed pronounced leukocytic infiltrates in
skin, liver, spleen, joint, sinus, conjunctiva, bone marrow, and
tongue, which upon higher magnification were shown to be
mainly neutrophilic (Figure 1B and data not shown). There was
also evidence of substantial necrosis in the gut and kidney that
was not associated with inflammation (data not shown), sug-
gesting that the cause of death in these pups is due to multi-
system organ failure secondary to inflammation and necrosis.
Tissue sections of 7- to 9-day-old Nlrp3A350V/+CreZ and
Nlrp3A350V/+CreL mice were very similar.
Although the human L353Pmutation is considered milder than
A352V, only six Nlrp3L351P/+CreL pups were identified by geno-
typing and were discovered dead within 1 day of birth, suggest-
ing that they either were stillborn or died soon after birth. Many
stillborn pups were likely cannibalized before detection.
Numbers of total mice born (affected and unaffected) are shown
in Figure 1C, first column, and mutant pups observed alive on
days 1 and 2 are shown in the adjacent columns. Most
Nlrp3A350V/+CreT and Nlrp3L351P/+CreT mice survived normally
without phenotype, although inflammatory changes in the skin
and/or growth delay were noted in some older (>12 weeks)
mice, likely resulting from ‘‘leaky’’ CreT activity causing expres-
sion of mutant NLRP3.
Complete blood counts (CBCs) of both Nlrp3A350V/+CreZ and
Nlrp3A350V/+CreL pups showed very similar profiles: the overall
white blood cell count was only mildly elevated and pronounced
neutrophilia and thrombocytosis were evident (data not shown).
Similar hematological and skin findings have been described
consistently in CAPS patients (Goldbach-Mansky et al., 2006;
Hoffman et al., 2004). Given the similarities in the gross
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Inflammasome-Mediated Mouse Disease ModelsFigure 1. CAPS Mutations Cause Severe Inflammatory Disease
Lethal in the Perinatal Period
(A) Survival (top) and growth (bottom) curves for WT (n = 86, WT CreZ shown
only), Nlrp3A350V/+CreZ (n = 50), and Nlrp3A350V/+CreL (n = 40) mice. A log-rank
(Mantel-Cox) test comparing Nlrp3A350V/+CreZ and Nlrp3A350V/+CreL survivalphenotype, pathology, and white blood cell differential of
Nlrp3A350V/+CreZ and Nlrp3A350V/+CreL mice, it is clear that the
myeloid lineage plays a pivotal role in murine disease. To
examine this role more specifically, we focused on the
Nlrp3A350V/+CreL mice and myeloid cells from Nlrp3A350V/+CreT
and Nlrp3L351P/+CreT mice for further experimentation.
Multiple Cytokines Are Upregulated
in Nlrp3A350V/+CreL Mice
To investigate cytokine secretion in Nlrp3A350V/+CreL mice, we
performed a Luminex assay on serum obtained 6–8 days after
birth. Multiple cytokines, chemokines, and growth factors were
significantly elevated in Nlrp3A350V/+CreL mice compared to
wild-type littermates (Figure 2A), including IL-1b and IL-6, two
cytokines known to have major roles in CAPS inflammation
(Goldbach-Mansky et al., 2006). Consistent with pronounced
neutrophilia, the growth factor GCSF and neutrophil chemoat-
tractant KC were also upregulated. IL-18, which like IL-1b is pro-
cessed to a mature, secreted form by caspase-1, was also
increased (Figure 2A). The Th2 cell lineage cytokines IL-4, IL-9,
IL-10, and IL-13 showed varying amounts of upregulation, but
the classical Th1 cell cytokines IFN-g and IL-12 were not
substantially different fromWT, nor was IL-17 (Figure S2). Serum
TNF-a was not substantially different in Nlrp3A350V/+CreL mice
compared to WT mice (Figure 2A), a finding consistent with
previously described CAPS patients (Hoffman et al., 2004).
The increase in serum IL-1b and IL-6 raised the question as
to whether these cytokines might also be upregulated at the
tissue level. Accordingly, we performed immunohistochemistry
on inflamed skin sections from Nlrp3A350V/+CreL pups for IL-1b
and IL-6. Increased expression of both cytokines, IL-1b primarily
in the dermis and IL-6 in the epidermis, was noted (Figure 2B).
This is consistent with skin biopsies from CAPS patients and
implies a role for these cytokines in skin pathology (Hoffman
et al., 2004).
Inflammasome Function Is Similar in Cells
from Nlrp3A350V/+CreT and Nlrp3L351P/+CreT
Mice and CAPS Patients
Because theNlrp3A350V/+CreZ andNlrp3A350V/+CreLmice exhibit
such a severe phenotype, we wanted to confirm that inflamma-
some function in the mice was similar to human CAPS patients.
The innate immune stimulant lipolysaccharide (LPS) signals
through toll-like receptor 4 (TLR4) on the cell surface andmultiple
second messengers within the cell to cause upregulation of pro-
IL-1b synthesis. Release of mature IL-1b does not occur without
exogenously applied ATP, which is likely to be mediated through
the ATP-dependent P2X7 ion channel to increase potassium ion
efflux (Mariathasan et al., 2006). Mutation-positive CAPS patient
curves yielded a p value < 0.0001. Error bars shown for mean daily weights
on growth curves are SD (n = 1–17).
(B) Nlrp3A350V/+CreL, day 8, tissue sections from synovium, liver, meninges,
and conjunctiva, stained with hematoxylin and eosin at 103 and 403 (insets)
magnification.
(C) Birth table of pups resulting from CreL+/+ 3 Nlrp3A350VNeoR/+ or
Nlrp3L351PNeoR/+ matings, with 50% of offspring expected to be mutant.
Shown: total pups; total mutant pups days 1 and 2 after birth.Immunity 30, 875–887, June 19, 2009 ª2009 Elsevier Inc. 877
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Inflammasome-Mediated Mouse Disease ModelsFigure 2. Multiple Cytokines Are Upregulated in the Serum and Skin of Nlrp3A350V/+CreL Mice
(A) Luminex analysis of serum obtained at days 6–8 fromWT andNlrp3A350V/+CreL pups, n = 10–12mice, each graph point represents onemouse, mean and SEM
are shown.
(B) Immunohistochemistry on skin fromWT andNlrp3A350V/+CreL pups for IL-1b or IL-6 (red stain), and an isotype control followed by hematoxylin staining. Similar
staining was observed on sections from Nlrp3A350V/+CreZ mice (not shown).cells have been shown to secrete IL-1b in the absence of ATP,
perhaps because the CAPS mutation renders NLRP3 constitu-
tively active (Gattorno et al., 2007). To determine whether
mutant mouse cells are also capable of secreting IL-1b without
ATP, we stimulated tamoxifen-treated bone marrow-derived
dendritic cells (BMDC) from Nlrp3A350V/+CreT, Nlrp3L351P/
+CreT, and WT adult mice with different LPS preparations and/
or ATP. ELISA analysis of supernatants showed no IL-1b release
fromWT BMDC at LPS concentrations below 10 ng/ml, whereas
IL-1b was easily detectable from mutant BMDC at 0.1 ng/ml,
suggesting that mutant cells are hyperresponsive. Maximal
IL-1b release was observed from all BMDCs at 10 ng/ml;
however, Nlrp3A350V/+CreT and Nlrp3L351P/+CreT BMDC
secreted amounts of 300 and 150 times, respectively, that of
WT BMDC (Figure 3A).878 Immunity 30, 875–887, June 19, 2009 ª2009 Elsevier Inc.The IL-1b secretion observed from WT cells implicated
possible ATP contamination in our crude LPS preparation. To
further characterize the stimulus requirement in Nlrp3A350V/+
CreT and Nlrp3L351P/+CreT, we treated BMDC with a highly puri-
fied preparation of LPS (100 ng/ml), with and without ATP, and
measured IL-1b secretion. Consistent with previous results,
WT cells did not secrete appreciable amounts of IL-1b in the
absence of ATP, but mutant cells released high amounts of
IL-1b with LPS alone (p < 0.0001) (Figure 3B). As expected, the
addition of ATP resulted in IL-1b release fromWT cells; however,
we also observed a 2- to 3-fold upregulation in secretion from
Nlrp3A350V/+CreT and Nlrp3L351P/+CreT cells (p = 0.008 and
0.004). When this experiment was repeated in Nlrp3A350V/+CreT
and Nlrp3L351P/+CreT peritoneal macrophages (PM), mutant
cells again secreted IL-1b in the absence of ATP (Figure 3C).
Immunity
Inflammasome-Mediated Mouse Disease ModelsFigure 3. Myeloid Cells from Nlrp3A350V/+CreT and Nlrp3L351P/+CreT Mice and CAPS Patients React Similarly to Innate Stimuli
(A and B) Tamoxifen-treated Nlrp3A350V/+CreT, Nlrp3L351P/+CreT, and littermateWT BMDCwere incubated with varying amounts of (A) crude LPS or (B) pure LPS
(100 ng/ml) with and without ATP (5 mM).
(C) Tamoxifen-treated peritoneal macrophages (PM) were incubated with pure LPS with and without ATP.
(A–C) n = 2–3 mice with 3 wells each/genotype. Bar graphs show mean + SD.
(D) Immunoblotting for IL-1b or actin loading control, Nlrp3A350V/+CreT BMDC lysates (left), and supernatants (right).
(E) In vitro stimulation of monocytes from three CAPS patients and three normal human controls with pure LPS with and without ATP.
(F) In vitro cold stimulation of WT, Nlrp3A350V/+CreT, and Nlrp3L351P/+CreT BMDC, n = 2–3. Cells were incubated at 32C overnight.
(G) In vitro cold stimulation of monocytes from five FCAS patients and two normal human controls, 4 hr and overnight. Also shown, incubation at 37C.
(A–C, E–G) IL-1b in the supernatants was measured by ELISA.The amounts of IL-1b secreted by these cells with or without ATP
were much lower than those observed with BMDC, probably
because of a lower cell concentration. Interestingly, a small
amount of IL-1b was released in the absence of any stimulus
from Nlrp3L351P/+CreT BMDC (Figures 3A and 3B), but not from
PM (Figure 3C).
IL-1b is first synthesized as a 34 kDa proprotein, which is
cleaved by caspase-1 to the 17 kDa mature form. To determine
which form is secreted, we performed immunoblotting analysis
on the Nlrp3A350V/+CreT cell supernatants used for ELISA. For
comparison, we probed lysates of LPS and/or ATP-stimulated
cells. Nlrp3A350V/+CreT BMDC secreted primarily mature IL-1b,as well as some pro-IL-1b, whereas pro-IL-1b predominated in
cell lysates (Figure 3D). A small amount of pro-IL-1b was de-
tected in the supernatants from all cells treated with LPS and
ATP, possibly because of cell lysis, because a slight drop in
cell viability was observed after incubation with ATP. WT and
Nlrp3A350V/+CreT lysates contained similar amounts of pro-IL-
1b, independent of ATP, indicating that ATP is necessary only
for secretion of IL-1b and not for synthesis.
As a comparison to stimulations done on murine cells, we also
stimulated monocytes from three mutation-positive MWS or
NOMID patients, human mutations D303N or R260W (Dode
et al., 2002), with LPS, with and without ATP. Patient cells, butImmunity 30, 875–887, June 19, 2009 ª2009 Elsevier Inc. 879
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whereas both controls and CAPS secreted in response to LPS
and/or ATP (Figure 3E).
FCAS patients suffer inflammatory attacks upon brief expo-
sure to cold temperatures, and peripheral blood monocytes
from patients secrete IL-1b spontaneously when incubated at
32C (Rosengren et al., 2007). To determine whether
Nlrp3A350V/+CreT and Nlrp3L351P/+CreT cells were also stimu-
lated by low temperatures, we incubated BMDC at 32C and
stimulated with varying amounts of crude LPS. Nlrp3L351P/+
CreT spontaneously secreted high amounts of IL-1b at 32C
(p = 0.013) (Figure 3F), consistent with monocytes from FCAS
patients, with a further upregulation in secretion with LPS. In
contrast, incubation at 32C alone did not result in secretion
from Nlrp3A350V/+CreT cells. These cells secreted as expected
when stimulated with LPS, with a trend of higher IL-1b release
at 0.1 ng/ml LPS than previously at 37C (Figure 3A). This
suggests that temperature might have an activating effect on
these cells as well, although it is not enough to cause secretion
in the absence of stimulant. PM from Nlrp3L351P/+CreT did not
secrete spontaneously at 32C (data not shown), indicating
that not all myeloid cell sources in these mice are temperature
responsive. As a comparison, we tested a family of five FCAS
patients, human mutation F523C (Aksentijevich et al., 2007),
for spontaneous secretion. Similar to cells from mice, patient
monocytes robustly secreted IL-1b when incubated at 32C
(Figure 3G).
Disease Expression in Mice Is Partially Dependant
on IL-1b
CAPS patients treated with the IL-1b inhibitors Anakinra (Amgen)
or Rilonacept (Regeneron) have almost complete resolution of
symptoms and normalization of serum markers of inflammation
(Goldbach-Mansky et al., 2006; Hoffman et al., 2008). Because
Nlrp3A350V/+CreL pups show similar cellular infiltrates, CBCs,
and increased serum and tissue concentrations of IL-1b, we
hypothesized that IL-1b inhibition would ameliorate murine
disease. We treated Nlrp3A350V/+CreL pups from birth or soon
after with a mouse form of Rilonacept, mIL-1 Trap. Pups injected
subcutaneously every other day survived on average 3 days
longer than vehicle-injected littermates (p = 0.003, Figure 4A),
despite doses up to 60 times those used normally in humans.
Wild-type littermates given equal doses of mIL-1 Trap grew
and gained weight normally, but mIL-1 Trap did not significantly
increase Nlrp3A350V/+CreL growth rate (Figure 4A), nor did it
visibly impact skin pathology.
Because it is impossible to know how efficiently mIL-1 Trap
inhibits endogenousmouse IL-1b in neonate tissues, we decided
to assess IL-1b’s role in a more definitive manner. We first mated
Nlrp3A350VneoR/+ and Nlrp3L351PneoR/+ mice to Il1r1/ mice,
which do not express the IL-1 receptor (Glaccum et al., 1997),
and then bred these mice to the CreL line. Nlrp3A350V/+CreL
Il1r1/ mice were essentially protected from neonatal lethality,
with improved weight gain compared to Nlrp3A350V/+CreL and
Nlrp3A350/+CreL Il1r1+/mice (Figure 4B). However, growth rates
were variable within litters, with some pups indistinguishable
from WT and others growing more slowly. Some signs of limited
cutaneous inflammation were observed and these were also
variable within litters (data not shown).880 Immunity 30, 875–887, June 19, 2009 ª2009 Elsevier Inc.Although the expression of L351P appears to result in perinatal
lethality on an intact Il1r1 background, most Nlrp3L351P/+CreL
Il1r1/ mice were born with a milder phenotype compared to
Nlrp3A350V/+CreL mice, with less prominent skin or hair findings
and improved growth. Additionally, all Nlrp3L351P/+CreL Il1r1/
mice survived at least 10 days. Approximately 80% of
Nlrp3L351P/+CreL Il1r1/ mice died by 35 days after birth, but
the remaining 20% were still alive after 75 days (Figure 4C).
This variability in survival and phenotype may be due to a mixed
genetic background, because the Il1r1/ mice are not fully
backcrossed.
To assess which cytokines are dependent on IL-1R signaling,
we performed a Luminex assay on serum from Nlrp3A350V/+CreL
Il1r1/ mice. A significant number of cytokines previously
upregulated in Nlrp3A350V/+CreL mice on an intact Il1r1
background were now at amounts roughly equivalent to WT,
including KC, GCSF, IL-6, and IL-4 (Figure 4D; WT and
Nlrp3A350V/+CreLmeans from Figure 2A shown for comparison).
IL-1b serum concentrations inNlrp3A350V/+CreL Il1r1/mice did
not change, nor did IL-18, presumably because it is also cleaved
by caspase-1 and not dependent on activation of the IL-1R.
Nlrp3A350V/+CreT BMDC Drive an Inflammatory
Phenotype
FACS analysis of Nlrp3A350V/+CreZ splenocytes demonstrated
a pronounced neutrophilia consistent with the infiltrates
observed in other tissues (Figure S3). In addition, expression of
T cell activation markers CD69 and CD25, measured by mean
fluorescence intensity (MFI), was increased on both CD4+ and
CD8+ T cells (Figure S3 and data not shown), suggesting an
ongoing T cell process that could be mediated by dendritic cells.
As a first step, we stimulated WT and Nlrp3A350V/+CreT BMDC
with LPS and examined the expression of MHC class II antigen,
CD40, and OX40 ligand (OX40L), molecules known to be
involved in APC functions (Chen et al., 1999; Murata et al.,
2000; Ni and O’Neill, 1997). Although there was no difference
in expression of MHC II and CD40, LPS-activated Nlrp3A350V/+
CreT BMDC expressed higher amounts of surface OX40L
than did WT BMDC, measured by MFI (Figure 5A). Thus,
Nlrp3A350V/+CreT BMDC are primed to direct an inflammatory
T cell response.
To assess this response, we exposed BMDC to naive T cells
isolated from an OT II mouse (all T cells are derived from a single
clone specific for an ovalbumin peptide [OVA]) (Barnden et al.,
1998) under various polarizing conditions. When polarized
toward a Th1 cell profile, a substantially higher percentage of
T cells incubated withNlrp3A350V/+CreT BMDC stained positively
for IFN-g at low concentrations of OVA antigen, as measured by
MFI, with 31% of cells positive at an antigen concentration of
10 nM compared to 8% of cells incubated with WT BMDC
(Figure 5B). This percentage gradually increased to 74%, at
a concentration of 1 mM OVA, at which the two strains were
about equal. Higher amounts of antigen resulted in cell death,
probably because IFN-g amounts became cytotoxic (data not
shown). When polarized toward a Th17 cell phenotype, a 2-fold
increase in the number of IL-17-positive T cells cocultured with
Nlrp3A350V/+CreT BMDC was observed at 1 mM antigen concen-
trations (Figure 5C). Finally, when cells were left untreated, a
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Inflammasome-Mediated Mouse Disease ModelsFigure 4. IL-1b Is Required for Murine Disease
(A) Nlrp3A350V/+CreL and wild-type littermates were treated with subcutaneously injected mIL-1 Trap every other day beginning day 1–2 after birth. Survival (left)
(n = 9) and growth (right) (n = 2–9 mice), p = 0.003 by log-rank (Mantel-Cox) comparison.
(B) Survival (left) and growth (right) of Nlrp3A350V/+CreL Il1r1+/ and Nlrp3A350V/+CreL Il1r1/ mice (n = 13–18 for survival and 1–9 for growth).
(C) Survival (left) and growth (right) of Nlrp3L351P/+CreL Il1r1/mice (n = 33 for survival and 2–12 for growth). Error bars shown for mean daily weights on growth
curves are SD.
(D) Luminex analysis of serum from Nlrp3A350V/+CreL Il1r1/mice, n = 5, compared with Luminex data fromWT and Nlrp3A350V/+CreLmice in Figure 2 (averages
and SEM shown only).Immunity 30, 875–887, June 19, 2009 ª2009 Elsevier Inc. 881
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Inflammasome-Mediated Mouse Disease ModelsFigure 5. Nlrp3A350V/+CreT BMDC Drive an Inflammatory T Cell Phenotype
(A) Tamoxifen-treated BMDC from Nlrp3A350V/+CreT and WT mice were treated with LPS and stained for CD40, OX40L, and MHC class II receptor.
(B–I) BMDC were plated with OT II naive T cells and OVA antigen under Th1 (B, E), Th2 (C, F), or Th17 (H) cell polarizing conditions or left unpolarized (D, G, I).
(B–D) Flow cytometry analysis of intracellular IFN-g and IL-17.
(E–I) Luminex analysis of culture supernatants for IFN-g, IL-17, IL-5, and IL-4.2-fold increase in IL-17-positive cells was observed from
Nlrp3A350V/+CreT cells at the highest (10 mM) antigen concentra-
tion (Figure 5D). Luminex analysis of supernatants was consis-
tent with the flow cytometry results (Figures 5E–5G) and also
demonstrated a modest increase in secreted IL-5 from
Nlrp3A350V/+CreT cells polarized to a Th2 cell phenotype at higher882 Immunity 30, 875–887, June 19, 2009 ª2009 Elsevier Inc.antigen concentrations (Figure 5H). A small increase in secreted
IL-4 in unpolarized Nlrp3A350V/+CreT wells at intermediate anti-
gen concentrations (Figure 5I) was also observed. Thus, these
results suggest that given the right culture milieu, Nlrp3A350V/+
CreT BMDC can efficiently direct a variety of T cell responses,
but when left unpolarized promote a Th17 cell phenotype.
Immunity
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Not Require T Cells or Wild-Type NLRP3
The elevated numbers of activated T cells in our mice and the
robust response from naive T cells stimulated with Nlrp3A350V/+
CreT antigen-presenting cells suggested a contributing role for
T cells in murine disease. To determine whether T cells play
a role in disease pathology, we mated Nlrp3A350VneoR/+ mice
with Rag1/ mice, which contain no mature T or B cells (Mom-
baerts et al., 1992), and then mated to CreL. Nlrp3A350V/+CreL
Rag1/ mice died at approximately the same time as
Nlrp3A350V/+CreLmice on an intact or haplosufficientRag1 back-
ground, with similar cutaneous inflammation and growth delay
(Figures 6A and 1B and data not shown). These data suggest
that the observed T cell activation profile is not a major contrib-
uting factor to disease expression and mortality.
The NLRP3 inflammasome also includes caspase-1 and the
adaptor proteins, apoptosis-associated speck-like protein with
a caspase recruitment domain (ASC, encoded by Pycard) and
CARDINAL (Agostini et al., 2004). It is hypothesized that CAPS
mutations render the inflammasome constitutively active, inde-
pendent of PAMP or DAMP sensing, leading to enhanced activa-
tion of caspase-1 and overproduction of IL-1b. To determine
whether the inflammasome is necessary for the phenotype in
Nlrp3A350V/+CreL and perinatal lethality in Nlrp3L351P/+CreL
mice, we mated Nlrp3A350VneoR/+ and Nlrp3L351PneoR/+ mice to
Pycard/ mice (Hoffman et al., 2008; Kanneganti et al., 2006)
and then mated to CreL. Nlrp3A350V/+CreL Pycard+/ mice
exhibited survival kinetics similar to Nlrp3A350V/+CreL mice on a
Pycard-intact background, and Nlrp3L351P/+CreL Pycard+/
mice were not observed, suggesting that one Pycard allele is
sufficient for disease (data not shown). However, Nlrp3A350V/+
CreL Pycard/ and Nlrp3L351P/+CreL Pycard/ mice appeared
phenotypically normal and grew at a rate comparable to WT
siblings (Figures 6A and 6B). Taken together, these results
indicate that both NLRP3 mutants exert their effects via the
inflammasome.
Molecular models and studies with recombinant protein and
transfection systems suggest that NLRP3 self-associates
(Aksentijevich et al., 2007; Duncan et al., 2007). Because
CAPS is dominantly inherited with expression of both WT and
mutant alleles in all patients, WTNLRP3may be necessary for in-
flammasome oligomerization and disease phenotype. To deter-
mine the role of WT NLRP3 in the pathology of Nlrp3A350V/+CreL
mice, we bred Nlrp3A350VneoR/+ to an Nlrp3/ background
(Kanneganti et al., 2006; Sutterwala et al., 2006) and then bred
to CreL. The growth rate and survival of mice hemizygous for
NLRP3 A350V (Nlrp3A350V/CreL) was the same or decreased
compared to that of Nlrp3A350V/+CreL, indicating that WT protein
is not required for murine disease (Figures 6A and 1B).
DISCUSSION
We used CAPS mutant knockin mice expressing MWS and
FCAS mutations A350V and L351P to demonstrate a pivotal,
but not exclusive, role for IL-1b in the CAPS autoinflammatory
disease spectrum. Further, we showed that murine disease is
a genuine inflammasomopathy solely dependent on the innate
immune system and an intact inflammasome. Although an adap-
tive response occurs, it is not an important factor for the earlymortality and severe inflammation observed in these mice.
Although our mice have a more severe phenotype than MWS
and FCAS patients, we nonetheless consider them goodmodels
for human disease, because neutrophils are the predominant cell
type and IL-1b and IL-6 upregulated in our mice are also upregu-
lated in CAPS patients. At a cellular level, myeloid cells frommice
are similar to patient monocytes, because these cell types show
Figure 6. An Intact Inflammasome Is Required for Pathology
Mediated by NLRP3 Knockin Mutations, but T and B Cells Are Not
Nlrp3A350VneoR/+ mice were bred with Pycard/, Rag1/, and Nlrp3/ mice.
(A) Survival (top) and growth (bottom) of Nlrp3A350V/+CreL Rag1/ (n = 1–3 for
growth, 6 for survival), Nlrp3A350V/+CreL Pycard/ (n = 1–3 for growth, 7 for
survival), and Nlrp3A350V/CreL (n = 1–3 for growth, 7 for survival) mice.
(B) Survival (top) and growth (bottom) of Nlrp3L351P/+CreL Pycard/ mice
(n = 13 for survival, 2–3 for growth). Error bars shown for mean daily weights
on growth curves are SD.Immunity 30, 875–887, June 19, 2009 ª2009 Elsevier Inc. 883
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Additionally, both FCAS patient cells and BMDC from the
Nlrp3L351P/+CreT line secrete IL-1b when exposed to 32C.
Although FCAS is generally considered a milder form of CAPS
than MWS, expression of L351P resulted in perinatal or
presumed intrauterine mortality. The inflammatory phenotype
observed in A350V-expressing mice is usually apparent on the
day of birth, but some pups could not be distinguished from
WT littermates the following day, suggesting that the phenotype
begins at birth or shortly after. An explanation for why the L351P
FCAS mouse phenotype is more severe could be provided by
in vitro studies, in which we showed Nlrp3L351P/+CreT BMDC
had increased spontaneous IL-1b secretion compared to
Nlrp3A350V/+CreT. This was also observed in patient monocytes
in this study. If this spontaneous secretion occurs in vivo, the
inflammatory phenotype may begin before birth. It is also
possible that exposure to room temperature at birth could result
in perinatal mortality in Nlrp3L351P/+CreL mice.
IL-1b inhibition treatment generally resolves symptoms and
normalizes laboratory evidence of inflammation in most CAPS
patients (Goldbach-Mansky et al., 2006; Hoffman et al., 2004,
2008); however, mouse IL-1 Trap extended Nlrp3A350V/+CreL
survival only a few days, with no improvement in skin findings
or growth. No pharmacokinetic information for mIL-1 Trap is
available, making it possible that drug concentrations in tissues
do not reach therapeutic levels. It is also possible that initiation of
mIL-1 Trap therapy in the first few days of life is too late. Treat-
ment of pregnant mice did not have any effect on the phenotype
of pups (data not shown); however, it is also not known whether
mIL-1 Trap crosses the placenta.
The increased lifespan of Nlrp3A350V/+CreL Il1r1/ and live
birth of Nlrp3L351/+CreL Il1r1/ mice is definitive proof of
IL-1b’s central role in this murine disease; however, the residual
phenotype in some Nlrp3A350V/+CreL Il1r1/ and early mortality
in most Nlrp3L351P/+CreL Il1r1/ mice implicate IL-1b-indepen-
dent pathways. Il1r1/ prevents IL-1b signaling, but does not
affect the release of IL-1b or other caspase-1-activated cyto-
kines, such as IL-18 and IL-33. Serum IL-1b and IL-18 concen-
trations remained elevated in the Nlrp3A350V/+CreL Il1r1/
mice, as expected. Most of the other upregulated cytokines
were normalized, although mild increases in some were still
evident (data not shown), perhaps because these are IL-18 or
IL-33 dependent. It is possible that treatment with anti-IL-18 or
soluble ST2 (IL-33) receptor will rescue the residual phenotype
(Kakkar and Lee, 2008).
Crossing onto a Pycard/ background completely rescued
the phenotype for both mutations, providing definitive proof
that these mutations are true gain-of-function lesions acting
through the inflammasome. Studies in overexpression systems
suggest that high amounts of NLRP3 cause spontaneous secre-
tion of IL-1b (Agostini et al., 2004; Dowds et al., 2004), and there-
fore it is possible that CAPS manifestations are due to increased
expression of NLRP3. We were unable to measure NLRP3
protein amounts endogenously, because the protein is not highly
expressed and specific antisera are lacking. Preliminary
qRTPCR analysis of NLRP3 mRNA in BMDC did not show
a consistent increase in mutants (data not shown), although it
is possible that NLRP3 protein is upregulated without an
increase in message. A second hypothesis is that CAPS muta-884 Immunity 30, 875–887, June 19, 2009 ª2009 Elsevier Inc.tions affect the stability of NLRP3, perhaps increasing its half-
life. However, preliminary kinetic experiments with metabolic
labeling to follow tagged, overexpressed protein suggest that
the half-life of L353Pmutant NLRP3 is shorter than that of normal
protein at 37C (data not shown).
The mechanism behind the cold-induced IL-1b release in
FCAS patient monocytes and Nlrp3L351P/+CreT BMDC is not
well understood. Mechanisms proposed for other cold-sensitive
phenotypes are temperature-induced macromolecular changes
that affect protein function or intramolecular interactions, or
membrane alterations affecting fluidity (Pain, 1987; Thieringer
et al., 1998). It is also possible that cold temperatures could
affect the expression or stability of inflammasome components.
Metabolic labeling assays at 32C demonstrate an increase in
the half-life of L353P-mutated cryopyrin, suggesting that lower
temperatures stabilize protein that would normally be degraded
at 37C (data not shown). Further studies are needed to elucidate
the mechanisms involved.
Fulminant disease arising from mutant expression in the
myeloid lineage alone strongly implies that these cells are suffi-
cient for disease. However, subtle differences in survival kinetics
between the Nlrp3A350V/+CreL and Nlrp3A350V/+CreZ lines were
noted after many litters, indicating that nonmyeloid cells may
have an impact. Cryopyrin is mainly expressed hematopoieti-
cally, suggesting that this unidentified cell subset(s) is in the
immune lineage, although some expression has been demon-
strated in various types of epithelial cells as well (Kummer
et al., 2007). An ongoing T cell process in mutant mice is likely,
because BMDC were primed to direct a Th17 cell phenotype in
naive T cells. This is perhaps unsurprising, because stimulated
BMDC and mutant mouse serum contained high amounts of
IL-1b, a cytokine shown to be critically important to the Th17
cell phenotype in humans (Chen and O’Shea, 2008) and in
mice (Chung et al., 2009). Consistent with these studies, the
Th17 cell phenotype directed by Nlrp3A350V/+CreT BMDC was
abrogated when IL-1b signaling was blocked either pharmaco-
logically or genetically via the Il1r1/ background (data not
shown).
Although intriguing, the physiological relevance of the increase
in IL-17-positive T cells incubated with Nlrp3A350V/+CreT BMDC
is difficult to ascertain. Although KC, IL-6, and GCSF (all Th17
cell-associated cytokines) (Ouyang et al., 2008) were highly up-
regulated in serum, IL-17 itself was not. There was also no
increase in the skin or spleen of mRNA for IL-17 or IL-22, another
Th17 cell-associated cytokine (data not shown). Finally, the
contribution of any T cell response to disease in NLRP3 mutant
mice appears to be minimal. Breeding the mutation onto the
Rag1/ background demonstrated that T cells were not neces-
sary for inflammatory signs or mortality, suggesting that it is the
myeloid lineage alone and not its downstream effects on the
adaptive response that causes murine disease.
In conclusion, we have established mouse models for CAPS,
autoinflammatory syndromes arising from gain-of-function
mutations in NLRP3. These mouse models replicate many of
the clinical and pathologic features seen in humans, and mouse
in vitro responses to LPS and cold are also similar to those
observed in patient cells. However, the significance of IL-1b in
the mouse may differ from that in humans, as indicated by the
fact that inflammasome-mediated cytokines other than IL-1b
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Inflammasome-Mediated Mouse Disease Modelsappear to be important in murine disease. As a model of inflam-
masome dysregulation, these mice will be important in eluci-
dating the roles of the other caspase-1-dependent cytokines,
as well as testing novel therapeutic compounds. Our findings
suggest that the adaptive immune system is not necessary for
this inflammasome-mediated disease and that the innate
immune system and myeloid cells are the main pathogenic
players. Given the importance of IL-1b and the inflammasome
to innate immunity, NLRP3 knockin mice may be applied to the




The Nlrp3 knockin targeting constructs pPNTlox2PNlrp3A350V and
pPNTlox2PNlrp3L351P were created as follows. In brief, 4–7 kb regions
directly upstream and downstream of a targeted position in intron 2 were
cloned around the neoR antibiotic resistance cassette in plasmid pPNTlox2P
(Figure S1B). The alanine 350 to valine and leucine 351 to proline point muta-
tions in the 30 flank were engineered by site-directed mutagenesis with a Stra-
tagene Quik-change kit.
Knockin Mouse Generation
129 SvJ stem cells were electroporated with linearized pPNTlox2PNlrp3A350V
or pPNTlox2PNlrp3L351P via an established protocol by the UCSD mouse
transgenic core. Colonies heterozygous for A350V or L351P were selected
based upon Southern analysis and sequencing. Cre recombinase-mediated
excision of the neoR cassette and subsequent expression of the mutant allele
was confirmed by PCR and RT-PCR analysis, followed by sequencing. Subse-
quent mouse genotyping was performed with PCR.
Mouse Strains
The following mouse strains were used in this study: FVB/N-Tg(Zp3-Cre)3Mrt/
J (embryonic Cre expression; obtained from D. Cleveland [LICR] with permis-
sion of G. Martin [UCSF]); B6.129P2-Lyz2tm1(Cre)Ifo/J (myeloid Cre), B6.Cg-
Tg(Cre/Esr1)5Amc/J (tamoxifen-inducible Cre), B6.129S1-IL-1r1tm1Roml/J
(Il1r1/), B6.129S7-Rag1tm1Mom/J (Rag1/), C57BL/6-Tg(TcraTcrb)425Cbn/
J (OT-II), from Jackson Labs; and Pycard/, Nlrp3/ (provided by J. Bertin,
E. Grant, A. Coyle, and Millennium Pharmaceuticals). Mice were cared for in
accordance with appropriate institutional guidelines. The experimental proto-
colswere approvedby theUCSD Institutional AnimalCare andUseCommittee.
Peripheral Blood Analysis
Peripheral blood from 6- to 9-day-old pups was obtained after decapitation.
Complete blood counts (CBCs) were performed by the UCSD ACP Diagnostic
Laboratory. Serumwas analyzed by Luminex assay (Bio-Rad) according to the
manufacturer’s instructions.
Histologic Analysis
Mouse skin biopsy samples were fixed in 4%paraformaldehyde, embedded in
paraffin, sectioned, mounted on slides, deparaffinized, and rehydrated before
analysis. Sections were subjected to staining with anti-IL-6 (AF-406-NA) at
1:10 and anti-IL-1b (AF-401-NA) at 1:50 (R & D) for tissue cytokine analysis, fol-
lowed by secondary antibody and hematoxylin staining (Hoffman et al., 2004).
Treatment with mIL-1 Trap
100–200 mg/g mIL-1 Trap (provided by R. Torres and Regeneron Pharmaceu-
ticals) or diluent was injected subcutaneously in the dorsum of Nlrp3A350V/+
CreL pups and wild-type littermates every other day beginning within the first
2–3 days of life and continuing until death.
In Vitro Studies
Bone marrow cells from WT, Nlrp3A350V/+CreT, and Nlrp3L351P/+CreT adult
mice were plated in DMEM supplemented with 10% fetal calf serum, peni-
cillin/streptomycin, sodium pyruvate, and L-glutamate at 4 3 105 cells/wellin 96-well culture plates with GMCSF (20 ng/ml) (R and D). After 1 week, cells
were exposed to 1 mM 4-hydroxytamoxifen (Sigma) for 48 hr to stimulate
in vitro excision of neoR. For cold exposure, cells were incubated at 32Cover-
night and supernatants were collected. For LPS stimulation, cells were
cultured either overnight (crude LPS [Calbiochem]) or for 4 hr (pure LPS [Alexis
Biochemicals]), followed by incubation with 5 mM ATP for 30 min. Peritoneal
macrophages were plated at 5 3 104 cells/well in 96-well culture plates and
incubated overnight, followed by treatment with tamoxifen and stimulation
as described above.
Human peripheral blood mononuclear cells were isolated by Ficoll gradient,
followed by hypotonic lysis to remove erythrocytes. PBMCwere then plated at
105 cells/well in media without serum in a 96-well plate and monocytes were
allowed to adhere 3 hr at 37Cbefore the supernatant was replacedwithmedia
with 10%FCS. For cold-induced secretion studies, cells were incubated either
4 hr or overnight at 32C and 37C. For LPS stimulation, cells were stimulated
with 100 ng/ml LPS overnight, followed by treatment with 5mMATP for 30min.
Secreted IL-1bwasmeasured by ELISA (R and D). All human subject protocols
were approved by the institutional review board of the National Instititute of
Arthritis, Musculoskeletal, and Skin Diseases.
OT II T Cell and BMDC Coculture
To assess surface expression of MHC class II, CD40, and OX40L, BMDCwere
stimulated 24 hr with LPS and subjected to FACS analysis as described below.
For coculture experiments, WT or Nlrp3A350V/+CreT tamoxifen-treated BMDC
were incubated with a 10-fold excess of OT II naive CD4+ cells and varying
amounts of ovalbumin peptide (Peptides International). Cells were left
untreated or were stimulated with various cytokines and anti-cytokine
antibodies to direct distinct T helper lineages as follows: Th1: IL-12 and anti-
IL-4; Th2: IL-4 and anti-IFN-g; Th17: TGF-b and IL-6 plus anti-IL-2, anti-IL-4,
and anti-IFN-g. Antibodies were used at 10 mg/ml and cytokines were used
at 5–20 ng/ml. On day 3, cells were restimulated with PMA (50 ng/ml), ionomy-
cin (500 ng/ml), and 1:2000 diluted Golgi plug (BD PharMingen) for 4 hr, fol-
lowed by subsequent FACS analysis for intracellular cytokines as below.
Flow Cytometry
BMDC, cocultured OT II cells, or splenocytes were prepared, fixed, and
stained with PE, FITC, or APC-labeledmonoclonal antibodies (BD PharMingen
or EBioscience). Samples were acquired with a FACSCaliber (BD), followed by
analysis with FlowJo software.
Statistical Analyses
Statistical analyses and graphing were performed in Excel and Graphpad
Prism programs with the Student’s t test (Luminex analysis) and the log-rank
(Mantel-Cox) test (survival curve comparisons).
SUPPLEMENTAL DATA
Supplemental Data include three figures and can be found with this
article online at http://www.cell.com/immunity/supplemental/S1074-7613(09)
00233-7.
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